Register for our free email digests:
Latest From Summit Therapeutics PLC
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Arvinas Inc.
- Senior Management
Sean Cassidy, CFO
Robert Kleinfield, PhD, Chief Dev. Officer
- Contact Info
Phone: (203) 535-1456
395 Winchester Ave.
5 Science Park
New Haven, CT 06511
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.